Olumiant (baricitinib)

pCPA File Number: 21159

Negotiation Status:

Active Negotiation

Indication(s):

Subacute and chronic inflammatory joint diseases

Sponsor/Manufacturer:

Eli Lilly Canada Inc.

CADTH Project Number:

SR0597-000

pCPA Engagement Letter Issued:

2019-09-20

Negotiation Process Concluded:

Not Applicable